The Latest Breaking News from Pfizer

Paxlovid goes from COVID game-changer to pandemic enigma

The CDC recommends the new Pfizer-BioNTech booster for individuals 12 years and the Moderna vaccine for individuals 18 and up.

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

Moderna’s shot will be available to adults 18 and older, and Pfizer’s will be available to individuals 12 and older.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

The stock market has been down following Fed Chair Jerome Powell’s Jackson Hole speech that signaled continued monetary policy tightening. We think in this current volatile backdrop, people planning their retirement savings in their 30s should invest in fundamentally sound dividend-paying stocks Pfizer (PFE) and Costco (COST). Read more….

Government advisers are debating who should should get new updated COVID-19 boosters and when

The European Union’s drug regulator has recommended the use of two Omicron-tailored vaccines developed by the Pfizer-BioNTech partnership and Moderna Inc ahead of a fresh booster programme this fall across the continent.

On Sept. 1, 2022, the Centers for Disease Control and Prevention endorsed the use of updated COVID-19 booster shots that are specifically tailored to combat the two most prevalent omicron subvariants, BA.4 and BA.5. The decision comes just a day after the Food and Drug Administration’s emergency use authorization of…

The FDA today authorized the new booster, which could arrive as early as next week in Chicago, where nearly 2 million residents are expected to be eligible.